Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Expenses | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 |
| Operating Profit | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 |
| OPM % | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% |
| Other Income | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before tax | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% |
| Net Profit | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS in Rs | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Expenses | 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 533 | 583 |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 295 | 290 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% | 33% |
| Other Income | 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 | 11 |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 3 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 | 31 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 | 268 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | 24% | |
| Net Profit | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 | 24.65 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% | 4% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 16% | 22% | 28% | ||
| Compounded Profit Growth | % | 11% | 32% | 12% | ||
| Stock Price CAGR | % | % | 52% | 35% | ||
| Return on Equity | 23% | 20% | 19% | 19% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,182 |
| Borrowings | 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 |
| Other Liabilities | 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 115 | 154 |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 |
| Fixed Assets | 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 689 |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 |
| Other Assets | 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 453 | 534 |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,117 | 1,357 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | 186 |
| Cash from Investing Activity | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | -176 |
| Cash from Financing Activity | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | -10 |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | -0 |
| Free Cash Flow | -0 | 23 | 54 | 92 | 29 | -11 | -44 | -32 | 2 | 34 |
| CFO/OP | 158% | 141% | 97% | 146% | 61% | 51% | 73% | 86% | 86% | 84% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 | 97 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 | 229 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 | 159 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 | 167 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 | 147 |
| ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% | 25% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FIIs | 5.35% | 4.56% | 5.37% | 4.95% | 6.03% | 6.52% | 7.19% | 6.78% | 5.46% | 5.19% | 5.16% | 6.18% |
| DIIs | 7.17% | 5.39% | 5.30% | 5.48% | 5.45% | 4.93% | 4.26% | 4.86% | 5.22% | 5.00% | 5.70% | 5.30% |
| Public | 19.19% | 21.77% | 21.04% | 21.27% | 20.22% | 20.25% | 20.25% | 20.08% | 21.02% | 21.49% | 20.83% | 20.21% |
| No. of Shareholders | 92,991 | 95,929 | 87,980 | 89,621 | 85,328 | 89,394 | 91,051 | 91,928 | 87,912 | 85,099 | 81,161 | 82,082 |
Fundamentals
Market Cap₹ 7,928 Cr.
Current Price₹ 985
Stock P/E39.9
Book Value₹ 149
ROCE25.2 %
ROE19.1 %
Dividend Yield0.10 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)28%
Compounded Profit Growth (TTM)12%
Standalone figures.
Valuation
Market capRs 7,493 Cr
Enterprise valueRs 7,420 Cr
P/E (TTM)37.77x
Price to book6.26x
Price to sales8.59x
EV / EBITDA24.67x
EV / EBIT27.49x
EV / sales8.50x
Price to cash flow40.33x
Earnings yield2.65%
Dividend yield0.11%
P/E, 3-year average25.19x
P/B, 3-year average4.33x
P/E, 5-year average23.76x
P/B, 5-year average4.33x
Profitability
Operating margin (excl. other income)35.63%
Operating margin (incl. other income)36.96%
EBITDA margin34.47%
Pre-tax margin30.73%
Net profit margin22.74%
Net margin, latest quarter12.67%
ROE19.06%
ROCE25.17%
ROA16.90%
ROE, 3-year average18.51%
ROCE, 3-year average24.93%
ROA, 3-year average16.34%
ROE, 5-year average20.71%
ROCE, 5-year average27.26%
ROA, 5-year average17.26%
ROIC (approx.)18.27%
Tax rate23.90%
Other income / net worth0.92%
Growth
Sales growth (latest year)18.86%
Profit growth (latest year)11.26%
Sales CAGR, 3 years21.55%
Sales CAGR, 5 years16.17%
Profit CAGR, 3 years32.52%
Profit CAGR, 5 years11.09%
Sales growth QoQ-31.38%
Profit growth QoQ-67.61%
Sales growth YoY (latest quarter)30.80%
Profit growth YoY (latest quarter)-30.90%
Per share
EPS (TTM)Rs 24.65
EPS (latest year)Rs 25.98
EPS (latest quarter)Rs 2.99
EPS, 3-year averageRs 21.38
EPS, 5-year averageRs 18.83
Book value per shareRs 148.82
Sales per shareRs 108.41
Cash flow per shareRs 23.08
Free cash flow per shareRs 4.22
Dividend per share (latest year)Rs 1.00
Dividend per share, 3-year averageRs 0.93
Dividend per share, 5-year averageRs 0.80
Dividends
Dividend payout3.85%
Dividend payout, 3-year average4.51%
Dividend payout, 5-year average4.42%
Efficiency
Asset turnover0.61x
Fixed asset turnover1.20x
Inventory turnover2.28x
Inventory days160 days
Debtor days97 days
Debtors turnover3.77x
Creditor days159 days
Cash conversion cycle167 days
Working capital days147 days
Leverage
Total debtRs 5 Cr
Cash and bankRs 79 Cr
Net debtRs -73 Cr
Debt to equity0.00x
Net debt / EBITDA-0.24x
Interest coverage154.23x
Current ratio (filing 2026-03-31)4.40x
Quick ratio (filing 2026-03-31)3.08x
Trade payables (filing 2026-03-31)Rs 111 Cr
Owners' fund to total sources88.26%
Debt to assets0.40%
Cash flow
Cash from Operating Activity (latest year)Rs 186 Cr
Cash from Investing Activity (latest year)Rs -176 Cr
Cash from Financing Activity (latest year)Rs -10 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs 34 Cr
FCFE (approx.: FCF + change in debt)Rs 34 Cr
Cash from ops / profit, 5 years0.76x
Sales to cash flow4.46x
Statement figures
Net sales (TTM)Rs 873 Cr
Net sales (latest year)Rs 828 Cr
Sales (latest quarter)Rs 190 Cr
Operating profit excl. other income (latest year)Rs 295 Cr
Operating profit (latest quarter)Rs 47 Cr
Other income (TTM)Rs 11 Cr
EBITDA (TTM)Rs 301 Cr
PBDT (TTM)Rs 299 Cr
Profit before tax (TTM)Rs 268 Cr
Tax (latest year)Rs 66 Cr
Net profit (TTM)Rs 198 Cr
Net profit (latest year)Rs 209 Cr
Net profit (latest quarter)Rs 24 Cr
Depreciation (TTM)Rs 31 Cr
Depreciation (latest quarter)Rs 9 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 364 Cr
Total expenditure (latest year)Rs 533 Cr
Total income (latest year)Rs 839 Cr
Share capitalRs 16 Cr
ReservesRs 1,182 Cr
Shareholders' fundsRs 1,198 Cr
Total assetsRs 1,357 Cr
Net blockRs 689 Cr
Capital work in progressRs 36 Cr
InvestmentsRs 99 Cr
ReceivablesRs 219 Cr
InventoryRs 160 Cr
Other liabilitiesRs 154 Cr
Shares outstanding (crore)8.05
Ownership
Promoter holding68.30% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 37.8 is at the 86th percentile of its own 4.9-year range
(median 29.5, low 10.1, high 52.4).
P/B 6.26 is at the 71th percentile (median 5.34).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | SUPRIYA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.2% | -2.8% | -0.4 pts |
| 1 month | +15.9% | -6.8% | +22.7 pts |
| 3 months | -4.9% | -7.6% | +2.7 pts |
| 6 months | +65.7% | +0.4% | +65.3 pts |
| 1 year | +25.6% | -9.9% | +35.5 pts |
| 2 years | +48.3% | -13.6% | +61.9 pts |
| 3 years | +231.4% | +14.2% | +217.3 pts |
15 mutual fund schemes hold about ₹76 Cr.
Over three months 0 bought more and 15 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Abakkus Flexi Cap Fund | 0.58% | 37 | -41% |
| ITI Large & Mid Cap Fund | 1.41% | 10 | -16% |
| Quantum Small Cap Fund | 3.29% | 8 | -23% |
| ITI ELSS Tax Saver Fund | 1.58% | 7 | -19% |
| WOC Pharma and Healthcare Fund | 0.60% | 5 | -19% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.21% | 5 | -23% |
| ITI Pharma & Healthcare Fund | 0.81% | 2 | -17% |
| Angel One Nifty Total Market Momentum Quality 50 Index Fund | 0.13% | 0 | -18% |
| Groww Nifty Total Market Index Fund | 0.01% | 0 | -19% |
| Bandhan BSE Healthcare Index Fund | 0.13% | 0 | -21% |
| Angel One Nifty Total Market Index Fund | 0.01% | 0 | -19% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% | 0 | -19% |
| Samco Small Cap Fund | 0.00% | 0 | -100% |
| Mirae Asset Nifty Total Market Index Fund | 0.01% | 0 | -19% |
| Bandhan Nifty Total Market Index Fund | 0.01% | 0 | -19% |
Red flags
F-score 4 of 8| explain | Receivables outrunning sales Receivables grew 63% vs sales +19% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹190 Cr +31.0% vs Jun 2025.
Net profit ₹24 Cr -31.4%.
Against our estimate for Jun 2026: sales +0.3%, profit -48.6% big miss. Our estimate for Sep 2026: sales Rs 282 Cr, profit Rs 69 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-04 | Dividend - Re 1 Per Share | |
| 2025-09-04 | Dividend - Re 1 Per Share | |
| 2024-09-20 | Annual General Meeting/Dividend - Rs 0.80 Per Share | |
| 2023-09-15 | Annual General Meeting/Dividend - Re 0.60 Per Share | |
| 2022-09-01 | Annual General Meeting/Dividend - Re 0.60 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Supriya Lifescience Ltd?
Supriya Lifescience Ltd (SUPRIYA) has a market capitalisation of Rs 7,928 Cr. at the 2026-10-01 close.
What is the P/E ratio of Supriya Lifescience Ltd?
Supriya Lifescience Ltd trades at a P/E of 39.9 on trailing twelve-month profit, at the 2026-10-01 close.
What were Supriya Lifescience Ltd's latest quarterly results?
In the Jun 2026 quarter, Supriya Lifescience Ltd sales was Rs 190 Cr (+31.0% vs Jun 2025) and net profit was Rs 24 Cr.
What is the 52-week high and low of Supriya Lifescience Ltd?
The 52-week high is Rs 1,085.00 and the 52-week low is Rs 545.50.